Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from MDS patients.

Myelodysplastic syndrome (MDS) is characterized by activated inflammatory signaling and affects prognosis. Targeting inflammatory signaling may provide a way to treat the disease. We were curious whether there were changes in A20 in peripheral blood mononuclear cells (PBMC) of MDS patients. Therefore, we conducted a study with 60 clinical samples, including 30 MDS patients and 30 healthy controls. All patients with MDS were diagnosed and classified according to the criteria of the 2016 World Health Organization. The study was performed in accordance with the guidelines of the Declaration of Helsinki. Using Quantitative Real-Time RT-PCR, we discovered that A20 mRNA expression in PBMC of the MDS group was significantly lower than that in the control group (P < 0.001). Additionally, using Luminex Liquid Suspension Chip, we observed elevated plasma levels of pro-inflammatory IL-8 and TNF-α in the MDS group compared to the healthy control group (P < 0.001). We did not find a significant correlation between A20 mRNA and clinical characteristics (age, sex, concentration of hemoglobin, neutrophils count, platelets count, percent of blasts, and WHO classification) of the patients, nor between A20 mRNA and plasma cytokines (data not shown). Our study found down-regulated of A20 and increased levels of pro-inflammatory cytokines in the peripheral blood of MDS patients, providing further evidence for the activation of inflammatory signals in MDS.

Composition design and optimization of Fe-C-Mn-Al steel based on machine learning.

The purpose of this study is to explore the composition space of Fe-C-Mn-Al steel using machine learning in order to identify materials with high-strength mechanical properties. A dataset of 580 steel samples was collected from the literature, each containing information on elemental composition, heat treatment processes, specimen dimensions, and mechanical properties (ultimate tensile strength and total elongation). Eight common machine learning models were constructed to predict the ultimate tensile strength (UTS) and total elongation (TE) of the steel. It was observed that the random forest regression (RFR) model, when trained, demonstrated superior overall performance in predicting UTS, with an average absolute error of approximately 90 MPa, and TE, with an average absolute error of about 7.9%. Validation of the model using eight sets of data that were not part of the dataset revealed that the predictions were in close agreement with experimental results, indicating the strong predictive capability of the RFR model. Subsequently, the trained RFR model was used to explore the composition space of Fe-C-Mn-Al steel, identifying the top fifty combinations of elemental compositions and heat treatment parameters, all of which manifest high ultimate tensile strength (UTS). This provides valuable research directions and methods to expedite the development of high-strength Fe-C-Mn-Al steel.

Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.

OBJECTIVES: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL. METHOD: A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates. RESULTS: From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea. CONCLUSION: For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.